High-Density Lipoprotein in Patients with Diabetic Kidney Disease: Friend or Foe?

Area of Science:

• Cardiovascular Biology
• Metabolic Disorders
• Nephrology

Background:

• High-density lipoprotein (HDL) offers metabolic protection, including antioxidant and anti-inflammatory effects, with potential benefits for diabetes and kidney health.
• Diabetic kidney disease (DKD) is linked to alterations in HDL cholesterol (HDL-C) quantity and quality due to hyperglycemia and related metabolic derangements.
• Dysfunctional HDL negatively impacts pancreatic beta cells and kidney cells, contributing to DKD progression.

Purpose of the Study:

• To explore the multifaceted role of HDL in the context of diabetic kidney disease (DKD).
• To review the impact of altered HDL levels and function on DKD pathogenesis and progression.
• To discuss potential therapeutic strategies targeting HDL for DKD management.

Main Methods:

• Literature review of studies investigating HDL characteristics and function in DKD.
• Analysis of the relationship between HDL levels, HDL quality, and DKD development.
• Evaluation of interventions aimed at modulating HDL for renoprotective effects.

Main Results:

• Altered HDL quantity and function are associated with DKD, driven by factors like oxidative stress and inflammation.
• Interventions like recombinant HDL (rHDL) or apolipoprotein A-I (apoA-I) show promise in improving glycemic control and renal protection.
• A complex U-shaped relationship exists between HDL-C levels and DKD risk, suggesting high HDL levels may not always be protective.

Conclusions:

• HDL's role in DKD is complex, with both protective and detrimental aspects depending on its functional status.
• Therapeutic strategies should focus on enhancing HDL function rather than solely increasing HDL levels for effective DKD management.
• Further research is essential to fully understand HDL's intricate involvement in DKD and to develop targeted therapies.